Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 4.93 GBp
Change Today +0.375 / 8.24%
Volume 1.7M
VRP On Other Exchanges
Symbol
Exchange
London
OTC US
Frankfurt
As of 11:30 AM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

verona pharma plc (VRP) Snapshot

Open
4.55 GBp
Previous Close
4.55 GBp
Day High
5.05 GBp
Day Low
4.55 GBp
52 Week High
06/12/15 - 6.88 GBp
52 Week Low
10/31/14 - 1.05 GBp
Market Cap
49.7M
Average Volume 10 Days
1.2M
EPS TTM
-0.0032 GBp
Shares Outstanding
1.0B
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for VERONA PHARMA PLC (VRP)

Related News

No related news articles were found.

verona pharma plc (VRP) Related Businessweek News

No Related Businessweek News Found

verona pharma plc (VRP) Details

Verona Pharma plc, a clinical stage biopharmaceutical company, engages in the research, discovery, and development of therapeutic drugs for the treatment of acute and chronic respiratory diseases in the United Kingdom and North America. The company’s lead product is RPL554, an inhaled dual phosphodiesterase 3 and 4 inhibitor that has completed Phase I and II clinical trials used for the treatment of chronic obstructive pulmonary disease and asthma, as well as in pre-clinical testing for the treatment of cystic fibrosis. It is also developing novel anti-inflammatory polysaccharides (NAIPs) that are in basic research phase to treat various respiratory and inflammatory diseases. The company is based in London, United Kingdom.

11 Employees
Last Reported Date: 05/13/15

verona pharma plc (VRP) Top Compensated Officers

Chief Executive Officer and Executive Directo...
Total Annual Compensation: 261.7K GBP
Chief Financial Officer and Executive Directo...
Total Annual Compensation: 47.5K GBP
Executive Director and Member of Audit Commit...
Total Annual Compensation: 77.5K GBP
Compensation as of Fiscal Year 2014.

verona pharma plc (VRP) Key Developments

Verona Pharma plc Starts RPL554 Phase 2A Trial

Verona Pharma plc announced that the first patients have been dosed with RPL554 in a Phase 2a dose-finding trial in asthma patients using the company's new proprietary nebulised formulation. RPL554 is a novel inhaled PDE3/PDE4 inhibitor, currently in development as a nebulised treatment for acute exacerbations in chronic obstructive pulmonary disorder patients in a hospital or home-care setting. The nebulised bronchodilator market was worth approximately $1 billion in 2014 in the US. The study is being carried out in asthmatics as typically a dose response relationship to bronchodilators can be more accurately established in this group of patients, compared to COPD patients. In this trial, up to 30 patients with mild to moderate chronic asthma will each receive single doses of nebulised RPL554, from the very low dose to the high dose previously tested in the Phase 1b single ascending and multiple ascending dose studies of the same drug in healthy subjects. In this double-blind, placebo-controlled, crossover study each patient will also receive two different doses of nebulised salbutamol, a commonly used bronchodilator in these patients, and placebo. The primary objective of the trial is to establish the bronchodilator effect and duration of action of RPL554 in asthma patients. The study is being performed at Celerion and Skane University Hospital.

Verona Pharma plc Announces Successful Completion of the Second Phase of Multiple Ascending Dose Study

Verona Pharma plc announced the successful completion of the second phase of a Multiple Ascending Dose (MAD) study in which nebulised RPL554, a novel dual PDE3/PDE4 inhibitor, was administered to healthy subjects for up to five consecutive days at doses up to 16x larger than the previously used active dose. RPL554 is currently in development as a nebulised treatment for acute exacerbations in COPD patients in a hospital or home-care setting. The nebulised bronchodilator market was worth about $1 billion in 2014 in the US. The completed MAD study showed that the drug was well tolerated across all dose levels and no maximum tolerated dose was reached. As found in the interim results from the single ascending dose (SAD) part of this trial, repeat dosing with the new formulation resulted in a longer residence time for RPL554 in the lung and slower release into the blood stream, suggesting that twice daily dosing may be appropriate. The Company also announced the commencement of a multiple ascending dose study in up to 30 moderate chronic obstructive pulmonary disease (COPD) patients, where each dose will be given for five consecutive days. The primary objective here is to further confirm the safety and tolerability seen in earlier parts of the trial, as well as to investigate bronchodilation in these COPD patients. This study is the final part of a Phase I/II clinical trial with RPL554, using a new proprietary nebulised formulation.

Verona Pharma plc, Annual General Meeting, Jun 11, 2015

Verona Pharma plc, Annual General Meeting, Jun 11, 2015., at 10:30 GMT Standard Time. Location: SGH Martineau LLP, 5th Floor.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VRP:LN 4.93 GBp +0.375

VRP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for VRP.
View Industry Companies
 

Industry Analysis

VRP

Industry Average

Valuation VRP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 3.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VERONA PHARMA PLC, please visit www.veronapharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.